EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Development of a Pharmacogenomic-Clinical Model for Acenocoumarol Dose Prediction in Older Vietnamese Patients with Atrial Fibrillation

Nhut Minh Lam, Ngoc Nga Pham Thi, Diem Nguyen Thi, Trung Cang Huynh, Trung Son Le

Vascular Health and Risk Management · 2026-11 · Volume 22 · 1-17

DOI: 10.2147/vhrm.s648112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Health and Risk Management, 2026-11. Verfasst von Nhut Minh Lam und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acenocoumarol maintenance dose varies with clinical and pharmacogenetic factors, but evidence in older Southeast Asian patients is limited.

Objective

To develop and internally validate a pharmacogenomic–clinical model predicting stable weekly acenocoumarol dose in older Vietnamese patients with atrial fibrillation.

Methods

We studied 161 patients aged ≥ 60 years receiving stable acenocoumarol therapy. Clinical factors, Charlson Comorbidity Index (CCI), CYP2C9 *3 and VKORC1 − 1639G>A were assessed. A clinical model (age and CCI) was compared with an integrated model adding VKORC1 . Apparent R2 , mean absolute error (MAE) and root mean squared error (RMSE) were optimism-corrected using 2,000 bootstrap resamples. Calibration, residual diagnostics and HC3 robust inference were assessed.

Results

Mean age was 75.64 ± 7.74 years; 56.52% were women. The VKORC1 A-allele frequency was 82.61%, and CYP2C9 *3 frequency was 1.55%. Median stable doses were 5.0, 7.0 and 14.0 mg/week in AA, GA and GG carriers, respectively (P< 0.001). The integrated model improved apparent R2 from 0.180 to 0.788; optimism-corrected R2 was 0.158 versus 0.783. Optimism-corrected MAE was 1.187 versus 0.698 mg/week and RMSE was 1.667 versus 0.849 mg/week. Heteroscedasticity was detected (Breusch–Pagan P=0.005), and HC3 inference retained significant associations for age, CCI and VKORC1 . Excluding three GG carriers reduced adjusted R2 to 0.638.

Conclusion

Incorporating VKORC1 improved the internally assessed performance of an exploratory model for estimating stable acenocoumarol maintenance dose. However, the high explained variance was partly influenced by three GG carriers, all receiving 14.0 mg/week; this small subgroup limits the precision and generalizability of genotype-specific predictions. Independent external validation is required before clinical implementation.

Zitieren

APA

Lam, N. M., Thi, N. N. P., Thi, D. N., Huynh, T. C., & Le, T. S. (2026). Development of a Pharmacogenomic-Clinical Model for Acenocoumarol Dose Prediction in Older Vietnamese Patients with Atrial Fibrillation. Vascular Health and Risk Management, Volume 22, 1-17. https://doi.org/10.2147/vhrm.s648112

Vancouver

Lam NM, Thi NNP, Thi DN, Huynh TC, Le TS. Development of a Pharmacogenomic-Clinical Model for Acenocoumarol Dose Prediction in Older Vietnamese Patients with Atrial Fibrillation. Vascular Health and Risk Management. 2026;Volume 22:1-17. doi:10.2147/vhrm.s648112

BibTeX
@article{Lam2026,
  author = {Lam, Nhut Minh and Thi, Ngoc Nga Pham and Thi, Diem Nguyen and Huynh, Trung Cang and Le, Trung Son},
  title = {Development of a Pharmacogenomic-Clinical Model for Acenocoumarol Dose Prediction in Older Vietnamese Patients with Atrial Fibrillation},
  journal = {Vascular Health and Risk Management},
  year = {2026},
  volume = {Volume 22},
  pages = {1--17},
  doi = {10.2147/vhrm.s648112}
}
Kostenlos starten →